Avenue Therapeutics, Inc. Stock
Avenue Therapeutics, Inc. Stock price
Key metrics
| Market capitalization | $690.00k |
| Enterprise Value | $-2.81m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.40 |
| P/B ratio (TTM) P/B ratio | 0.20 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-9.49m |
| Free Cash Flow (TTM) Free Cash Flow | $-7.10m |
| Cash position | $3.50m |
Is Avenue Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Avenue Therapeutics, Inc. Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Avenue Therapeutics, Inc.:
Analyst Opinions
1 Analyst has issued a forecast Avenue Therapeutics, Inc.:
Financial data from Avenue Therapeutics, Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -9.49 -9.49 |
20%
20%
|
| Net Profit | -9.16 -9.16 |
28%
28%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Avenue Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Alexandra MacLean |
| Employees | 2 |
| Founded | 2015 |
| Website | avenuetx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
